Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
322 stopped studies mapped to Chronic Leukemia and descendants · 84% state a reason
Over the 322 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT01629511 | Allogeneic Stem Cell Transplant for CLL | Phase 1 / Phase 2 | terminated | Jun 27, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01010256 | The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic… | — | terminated | Nov 9, 2009 | University of Arkansas | PI moved institutions | Other (stated, no rule matched) |
| NCT04043845 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | Phase 1 | withdrawn | Aug 2, 2019 | Dana-Farber Cancer Institute | Business development reasons. | Sponsor / business decision |
| NCT00899431 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | Phase 2 | terminated | May 12, 2009 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of continuing review | Other (stated, no rule matched) |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT02557516 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or… | Phase 1 / Phase 2 | terminated | Sep 23, 2015 | Innate Pharma | Sponsor decision | Sponsor / business decision |
| NCT00022971 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | Phase 1 | terminated | Aug 20, 2001 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01754870 | Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by… | Phase 2 | withdrawn | Dec 21, 2012 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT02784834 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | Phase 1 | terminated | May 27, 2016 | Michael Choi | lack of funding | Funding |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2015 | Emory University | not stated | Not stated |
| NCT01090414 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101;… | Phase 1 / Phase 2 | terminated | Mar 22, 2010 | Gilead Sciences | not stated | Not stated |
| NCT01539291 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who… | Phase 3 | terminated | Feb 27, 2012 | Gilead Sciences | not stated | Not stated |
| NCT00949988 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia(BMS-CA180105) | Phase 1 / Phase 2 | terminated | Jul 31, 2009 | University of California, San Diego | Three subjects were enrolled and all three subjects withdrew. | Enrollment / accrual |
| NCT01659021 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated… | Phase 3 | terminated | Aug 7, 2012 | Gilead Sciences | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk… | Phase 1 | terminated | Apr 25, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study drug supply expired and could not be renewed. | Drug supply |
| NCT02993536 | Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab | — | withdrawn | Dec 15, 2016 | Abramson Cancer Center at Penn Medicine | Low likelihood to usedrug in clinic practice based on emergining AE profile and data from front… | Other (stated, no rule matched) |
| NCT00829647 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Jan 27, 2009 | Scripps Health | Unable to enroll | Enrollment / accrual |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or… | Phase 1 / Phase 2 | terminated | Apr 16, 2015 | Spirita Oncology, LLC | Insufficient efficacy in Phase 1 dose-escalation portion of study | Efficacy / futility |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and… | Phase 4 | terminated | Jan 26, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT00648739 | Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM | Phase 1 / Phase 2 | terminated | Apr 1, 2008 | Alexion Pharmaceuticals, Inc. | The study was terminated by the Sponsor for administrative reasons and not due to any safety… | Safety / toxicity |
| NCT01403246 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With… | Phase 1 / Phase 2 | terminated | Jul 27, 2011 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Slow patient enrollment and new molecules for chronic lymphoid leukemia, have importantly reduced… | Enrollment / accrual |
| NCT02611908 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic… | Phase 1 | withdrawn | Nov 23, 2015 | Michael Choi | No participants enrolled | Enrollment / accrual |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in… | Phase 3 | terminated | Nov 11, 2013 | Gilead Sciences | not stated | Not stated |
| NCT01203930 | A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL | Phase 2 | terminated | Sep 17, 2010 | Gilead Sciences | not stated | Not stated |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With… | Phase 2 | terminated | Jul 24, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Funding was unavailable to complete the study as originally planned. | Funding |
| NCT01490775 | Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib)… | N/A | terminated | Dec 13, 2011 | Rex Cancer Center, Raleigh, NC | Study was terminated due to lack of funding | Funding |
| NCT01598025 | Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an… | N/A | terminated | May 15, 2012 | Memorial Sloan Kettering Cancer Center | Closed due to poor accrual | Enrollment / accrual |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or… | Phase 1 | terminated | Jun 20, 2014 | Wake Forest University Health Sciences | Slow Accruals | Enrollment / accrual |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic… | Phase 2 | terminated | Sep 25, 2009 | National Cancer Institute (NCI) | Terminated due to slow accrual, PI left NIH and primary endpoint not met. | Investigator |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT01612988 | Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL(BOMP) | Phase 2 | terminated | Jun 6, 2012 | French Innovative Leukemia Organisation | Other drugs others studies | Other (stated, no rule matched) |
| NCT02020109 | Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia | — | withdrawn | Dec 24, 2013 | Maastricht Radiation Oncology | Logistics and financial | Funding |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants… | Phase 4 | terminated | Jan 6, 2011 | Hoffmann-La Roche | not stated | Not stated |
| NCT01069432 | Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic… | — | withdrawn | Feb 17, 2010 | Dartmouth-Hitchcock Medical Center | IRB delayed their review for an extensive period of time. Funding for this protocol is no longer… | Funding |
| NCT02137889 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or…(VAY736Y) | Phase 1 | terminated | May 14, 2014 | Novartis Pharmaceuticals | Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early… | Safety / toxicity |
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | Phase 2 | withdrawn | Feb 25, 2015 | University of California, San Diego | Study Not Activated Due to Contract Issues | Other (stated, no rule matched) |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01) | Phase 1 | terminated | Feb 27, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lack of accrual | Enrollment / accrual |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia… | Phase 2 | terminated | Oct 5, 2011 | European Institute of Oncology | low rate in patient accrual | Enrollment / accrual |
| NCT02200848 | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic… | Phase 1 | terminated | Jul 25, 2014 | Georgetown University | Recruitment difficulties and toxicity | Safety / toxicity |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in… | Phase 1 / Phase 2 | withdrawn | Jul 15, 2010 | Masonic Cancer Center, University of Minnesota | Replaced by a new study | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 4, 2020source: clinicaltrials